Medpace Holdings, Inc. $MEDP Shares Sold by Harel Insurance Investments & Financial Services Ltd.

Harel Insurance Investments & Financial Services Ltd. trimmed its position in Medpace Holdings, Inc. (NASDAQ:MEDP) by 11.4% during the first quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission (SEC). The fund owned 14,071 shares of the company’s stock after selling 1,809 shares during the period. Harel Insurance Investments & Financial Services Ltd.’s holdings in Medpace were worth $6,757,000 as of its most recent SEC filing.

A number of other large investors also recently bought and sold shares of the company. AQR Capital Management LLC lifted its stake in shares of Medpace by 31.6% in the 4th quarter. AQR Capital Management LLC now owns 1,349,703 shares of the company’s stock worth $758,061,000 after acquiring an additional 324,293 shares during the period. Wasatch Advisors LP boosted its holdings in Medpace by 14.0% in the 2nd quarter. Wasatch Advisors LP now owns 945,814 shares of the company’s stock valued at $296,853,000 after purchasing an additional 116,354 shares in the last quarter. Geode Capital Management LLC boosted its holdings in Medpace by 3.8% in the 4th quarter. Geode Capital Management LLC now owns 667,298 shares of the company’s stock valued at $374,836,000 after purchasing an additional 24,625 shares in the last quarter. Invesco Ltd. increased its position in Medpace by 18.9% during the 3rd quarter. Invesco Ltd. now owns 537,407 shares of the company’s stock worth $276,313,000 after purchasing an additional 85,517 shares during the period. Finally, Arrowstreet Capital Limited Partnership increased its position in Medpace by 19.4% during the 4th quarter. Arrowstreet Capital Limited Partnership now owns 375,033 shares of the company’s stock worth $210,637,000 after purchasing an additional 60,883 shares during the period. Hedge funds and other institutional investors own 77.98% of the company’s stock.

Medpace Stock Performance

MEDP stock opened at $529.23 on Thursday. The company has a 50 day moving average price of $473.64 and a two-hundred day moving average price of $494.66. The stock has a market capitalization of $15.11 billion, a P/E ratio of 33.26, a PEG ratio of 2.72 and a beta of 1.15. Medpace Holdings, Inc. has a one year low of $306.70 and a one year high of $628.92.

Medpace (NASDAQ:MEDP) last issued its quarterly earnings results on Wednesday, April 22nd. The company reported $4.28 earnings per share for the quarter, topping analysts’ consensus estimates of $3.74 by $0.54. The company had revenue of $706.60 million for the quarter, compared to analyst estimates of $697.82 million. Medpace had a return on equity of 120.89% and a net margin of 17.19%.The business’s revenue for the quarter was up 26.5% compared to the same quarter last year. During the same quarter in the prior year, the company posted $3.67 EPS. Medpace has set its FY 2026 guidance at 16.680-17.500 EPS. Research analysts forecast that Medpace Holdings, Inc. will post 17.04 earnings per share for the current fiscal year.

Insider Buying and Selling at Medpace

In related news, General Counsel Stephen P. Ewald sold 16,349 shares of Medpace stock in a transaction on Thursday, May 28th. The stock was sold at an average price of $450.00, for a total value of $7,357,050.00. Following the transaction, the general counsel owned 20,343 shares in the company, valued at approximately $9,154,350. This trade represents a 44.56% decrease in their ownership of the stock. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through the SEC website. Company insiders own 20.50% of the company’s stock.

Wall Street Analyst Weigh In

Several research firms have recently commented on MEDP. Royal Bank Of Canada reduced their price target on Medpace from $522.00 to $484.00 and set an “outperform” rating for the company in a report on Friday, April 24th. Mizuho upped their price objective on Medpace from $495.00 to $586.00 and gave the stock an “outperform” rating in a report on Monday. BMO Capital Markets cut their price objective on Medpace from $460.00 to $400.00 and set a “market perform” rating for the company in a research report on Friday, April 24th. Jefferies Financial Group lowered shares of Medpace from a “buy” rating to a “hold” rating and boosted their target price for the stock from $490.00 to $515.00 in a research report on Tuesday, July 7th. Finally, Weiss Ratings reiterated a “hold (c+)” rating on shares of Medpace in a report on Thursday, July 2nd. Two investment analysts have rated the stock with a Buy rating, twelve have issued a Hold rating and one has assigned a Sell rating to the company. According to MarketBeat.com, the stock currently has an average rating of “Hold” and an average target price of $469.50.

Medpace Profile

Medpace Holdings, Inc (NASDAQ: MEDP) is a global contract research organization (CRO) that provides comprehensive clinical development services to biotechnology, pharmaceutical and medical device companies. The company supports clinical trials across all phases (I–IV), offering end-to-end solutions designed to streamline the development process and accelerate the delivery of new therapies to market.

Medpace’s core service offerings include clinical pharmacology, regulatory affairs consulting, project management, central laboratory services, imaging, data management and biostatistics, pharmacovigilance and medical writing.